Last reviewed 2026-04-20 · How we verify

TOBRAMYCIN SULFATE

Tobramycin sulfate is a marketed antibiotic primarily indicated for the treatment of septicemia, with a key composition patent expiring in 2028. Its established presence in the market and mechanism of action provide a strong foundation against bacterial infections. The primary risk is the potential increase in generic competition following the patent expiry in 2028.

At a glance

Approved indications

• Septicemia
• Lower Respiratory Tract Infections
• Central Nervous System Infections
• Intra-abdominal Infections
• Skin, Bone, and Skin Structure Infections
• Complicated and Recurrent Urinary Tract Infections
• Serious Staphylococcal Infections
• Life-Threatening Gram-Negative Infections

Boxed warnings

• WARNINGS Patients treated with tobramycin injection and other aminoglycosides should be under close clinical observation, because these drugs have an inherent potential for causing ototoxicity and nephrotoxicity. Neurotoxicity, manifested as both auditory and vestibular ototoxicity, can occur. The auditory changes are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve impairment and nephrotoxicity may develop, primarily in patients having preexisting renal damage and in those with normal renal function to whom aminoglycosides are administered for longer periods or in higher doses than those recommended. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. The risk of aminoglycoside-induced hearing loss increases with the degree of exposure to either high peak or high trough serum concentrations. Patients who develop cochlear damage may not have symptoms during therapy to warn them of eighth-nerve toxicity, and partial or total irreversible bilateral deafness may continue to develop after the drug has been discontinued. Rarely, nephrotoxicity may not become apparent until the first few days after cessation of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible. Renal and eighth-nerve function should be closely monitored in patients with known or suspected renal impairment and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Peak and trough serum concentrations of aminoglycosides should be monitored periodically during therapy to assure adequate levels and to avoid potentially toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided. Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such accumulation, excessive peak concentrations, advanced age, and cumulative dose may contribute to ototoxicity and nephrotoxicity (see PRECAUTIONS ). Urine should be examined for decreased specific gravity and increased excretion of protein, cells, and casts. Blood urea nitrogen, serum creatinine, and creatinine clearance should be measured periodically. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of impairment of renal, vestibular, or auditory function requires discontinuation of the drug or dosage adjustment. Tobramycin injection should be used with caution in premature and neonatal infants because of their renal immaturity and the resulting prolongation of serum half-life of the drug. Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics, particularly other aminoglycosides (e.g., amikacin, streptomycin, neomycin, kanamycin, gentamicin, and paromomycin), cephaloridine, viomycin, polymyxin B, colistin, cisplatin, and vancomycin, should be avoided. Other factors that may increase patient risk are advanced age and dehydration. Aminoglycosides should not be given concurrently with potent diuretics, such as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity, and intravenously administered diuretics enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. Aminoglycosides can cause fetal harm when administered to a pregnant woman (see PRECAUTIONS ).

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Rash
• Itching
• Headache
• Fever
• Pain at injection site
• Lethargy
• Urticaria

Serious adverse events

• Ototoxicity (hearing loss)
• Vestibular toxicity (dizziness, vertigo)
• Nephrotoxicity (renal function changes)
• Granulocytopenia
• Thrombocytopenia
• Anemia
• Mental confusion
• Disorientation
• Exfoliative dermatitis
• Tinnitus

Key clinical trials

• Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection (NA)
• Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial (PHASE2)
• Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy (PHASE3)
• Acute Application of Antibiotic Powder in Open Fracture Wounds (PHASE4)
• Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA (PHASE3)
• Fluorometholone Study (PHASE2)
• Local Antibiotic Concentrations With Tissue Expanders in Breast Reconstruction (NA)
• Tobradex as Intracanal Medicament (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TOBRAMYCIN SULFATE CI brief — competitive landscape report
• TOBRAMYCIN SULFATE updates RSS · CI watch RSS